v3 Template
B

Borealis Biosciences

Biotechnology / Healthcare ~10 employees
Founded
--
Employees (Est.)
~10
1 leaders known
Total Funding
$150.0M
Funding Rounds
1
Last Funding
2024-08-22

About Borealis Biosciences

Borealis Biosciences is a company focused on developing RNA medicines to treat kidney diseases. Founded on the convergence of scientific and translational breakthroughs, it builds on the success of Chinook Therapeutics, acquired by Novartis in 2023. The company aims to address unmet needs in kidney disease treatment and improve patients' lives globally.

Products & Services

RNA Medicines for Kidney Disease:Innovative therapies targeting kidney diseases by directing RNA to kidney cells, addressing validated, causal targets that traditional modalities cannot effectively treat.

Specialties

RNA Therapeutics Kidney Disease Treatment Targeted Delivery of RNA Translational Systems Biology Data Sciences Translational Biology Chemistry DMPK Pharmacology

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series A
T: -
FT: Series A 		A: 150000000
MR: -
FA: $150 million
FAN: 150000000 		D: 2024-08-22
FD: 2024-08-22 		2 investors
Series A Latest
2024-08-22
$150.0M
2 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

C

Christian Hordo

CEO

Recent News

Borealis Biosciences Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Healthcare
Company Size
~10 employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro